JENTADUETO XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Jentadueto Xr, and what generic alternatives are available?
Jentadueto Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.
This drug has three hundred and seventy-five patent family members in forty-five countries.
The generic ingredient in JENTADUETO XR is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jentadueto Xr
A generic version of JENTADUETO XR was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for JENTADUETO XR?
- What are the global sales for JENTADUETO XR?
- What is Average Wholesale Price for JENTADUETO XR?
Summary for JENTADUETO XR
International Patents: | 375 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 1 |
Patent Applications: | 34 |
Drug Prices: | Drug price information for JENTADUETO XR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JENTADUETO XR |
What excipients (inactive ingredients) are in JENTADUETO XR? | JENTADUETO XR excipients list |
DailyMed Link: | JENTADUETO XR at DailyMed |


Recent Clinical Trials for JENTADUETO XR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Boehringer Ingelheim | Phase 1 |
Pharmacology for JENTADUETO XR
Drug Class | Biguanide Dipeptidyl Peptidase 4 Inhibitor |
Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Paragraph IV (Patent) Challenges for JENTADUETO XR
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
JENTADUETO XR | Extended-release Tablets | linagliptin; metformin hydrochloride | 2.5 mg/1000 mg 5 mg/1000 mg | 208026 | 1 | 2018-03-28 |
US Patents and Regulatory Information for JENTADUETO XR
JENTADUETO XR is protected by nine US patents and two FDA Regulatory Exclusivities.
Expired US Patents for JENTADUETO XR
EU/EMA Drug Approvals for JENTADUETO XR
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim International GmbH | Jentadueto | linagliptin, metformin hydrochloride | EMEA/H/C/002279 Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. |
Authorised | no | no | no | 2012-07-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for JENTADUETO XR
When does loss-of-exclusivity occur for JENTADUETO XR?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 0269
Patent: COMPOSICION FARMACEUTICA Y SUS USOS
Estimated Expiration: ⤷ Try for Free
Australia
Patent: 13229538
Patent: Pharmaceutical compositions comprising metformin and a DPP-4 inhibitor or a SGLT-2 inhibitor
Estimated Expiration: ⤷ Try for Free
Canada
Patent: 66421
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE LA METFORMINE ET UN INHIBITEUR DE DPP -4 OU UN INHIBITEUR DE SGLT -2 (PHARMACEUTICAL COMPOSITIONS COMPRISING METFORMIN AND A DPP -4 INHIBITOR OR A SGLT-2 INHIBITOR)
Estimated Expiration: ⤷ Try for Free
Chile
Patent: 14002325
Patent: Composicion farmaceutica que comprende metformina y un inhibidor de dpp-4 con preferencia linagliptina o un inhibidor de sglt-2 con preferencia 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno; y comprimido de administracion oral.
Estimated Expiration: ⤷ Try for Free
China
Patent: 4220049
Patent: Pharmaceutical compositions comprising metformin and DPP -4 inhibitor or SGLT-2 inhibitor
Estimated Expiration: ⤷ Try for Free
Eurasian Patent Organization
Patent: 1400986
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МЕТФОРМИН И ИНГИБИТОР DPP-4 ИЛИ ИНГИБИТОР SGLT-2
Estimated Expiration: ⤷ Try for Free
European Patent Office
Patent: 22544
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE LA METFORMINE ET UN INHIBITEUR DE DPP -4 OU UN INHIBITEUR DE SGLT -2 (PHARMACEUTICAL COMPOSITIONS COMPRISING METFORMIN AND A DPP -4 INHIBITOR OR A SGLT-2 INHIBITOR)
Estimated Expiration: ⤷ Try for Free
Hong Kong
Patent: 04953
Patent: 包含二甲雙胍和 抑制劑或 抑制劑的藥物組合物 (PHARMACEUTICAL COMPOSITIONS COMPRISING METFORMIN AND A DPP -4 INHIBITOR OR A SGLT-2 INHIBITOR DPP-4 SGLT-2)
Estimated Expiration: ⤷ Try for Free
India
Patent: 01DEN2014
Estimated Expiration: ⤷ Try for Free
Japan
Patent: 15509519
Patent: メトホルミン及びDPP−4阻害薬又はSGLT−2阻害薬を含む医薬組成物
Estimated Expiration: ⤷ Try for Free
Mexico
Patent: 14010560
Patent: COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN METFORMINA Y UN INHIBIDOR DE DPP-4 O UN INHIBIDOR DE SGLT-2. (PHARMACEUTICAL COMPOSITIONS COMPRISING METFORMIN AND A DPP -4 INHIBITOR OR A SGLT-2 INHIBITOR.)
Estimated Expiration: ⤷ Try for Free
Philippines
Patent: 014501984
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING METFORMIN AND A DPP-4 INHIBITOR OR A SGLT-2 INHIBITOR
Estimated Expiration: ⤷ Try for Free
Singapore
Patent: 201405509U
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING METFORMIN AND A DPP -4 INHIBITOR OR A SGLT-2 INHIBITOR
Estimated Expiration: ⤷ Try for Free
South Korea
Patent: 140131950
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING METFORMIN AND A DPP-4 INHIBITOR OR A SGLT-2 INHIBITOR
Estimated Expiration: ⤷ Try for Free
Taiwan
Patent: 1400144
Patent: Pharmaceutical composition and uses thereof
Estimated Expiration: ⤷ Try for Free
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering JENTADUETO XR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Argentina | 060757 | USOS DE INHIBIDORES DE DPP IV | ⤷ Try for Free |
Eurasian Patent Organization | 016166 | 8-[3-АМИНОПИПЕРИДИН-1-ИЛ]КСАНТИНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ (8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS) | ⤷ Try for Free |
Brazil | PI0911273 | ⤷ Try for Free | |
Japan | 2000513028 | ⤷ Try for Free | |
World Intellectual Property Organization (WIPO) | 9938501 | ⤷ Try for Free | |
European Patent Office | 2287164 | Procédé pour la préparation des 8-(3-aminopiperidin-1-yl)-xanthines chirales (Process for the manufacture of chiral 8-(3-aminopiperidin-1-yl)-xanthines) | ⤷ Try for Free |
Canada | 2819705 | PROCEDE DE REGULATION DU METABOLISME DU GLUCOSE ET REACTIFS AFFERENTS (METHOD OF REGULATING GLUCOSE METABOLISM, AND REAGENTS RELATED THERETO) | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for JENTADUETO XR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1532149 | C20110018 00046 | Estonia | ⤷ Try for Free | PRODUCT NAME: TRAJENTA-LINAGLIPTIN; REG NO/DATE: FINAL 24.08.2011 |
1084705 | C300708 | Netherlands | ⤷ Try for Free | PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001-011 20111224 |
1532149 | 132013902118390 | Italy | ⤷ Try for Free | PRODUCT NAME: LINAGLIPTIN + METFORMINA CLORIDRATO(JENTADUETO); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/780/001 A EU/1/12/780/027, 20120720 |
1084705 | PA2014045 | Lithuania | ⤷ Try for Free | PRODUCT NAME: ALOGLIPTINUM; REGISTRATION NO/DATE: EU/1/13/844/001-027 20130919 |
1084705 | CR 2014 00066 | Denmark | ⤷ Try for Free | PRODUCT NAME: ALOGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER ALOGLIPTIN BENZOATE; REG. NO/DATE: EU/1/13/844/001-027 20130923 |
1084705 | SPC/GB14/083 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: ALOGLIPTIN; REGISTERED: UK EU/1/13/844 20130923 |
1084705 | CR 2014 00062 | Denmark | ⤷ Try for Free | PRODUCT NAME: SAXAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SAXAGLIPTIN HYDROCHLORID; REG. NO/DATE: EU/1/09/545/001-015 20091005 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for JENTADUETO XR
More… ↓